UCB Patch Product for Parkinson's Passes China Phase III Test

UCB, the Belgian biopharma, reported positive results from a China Phase III trial of its transdermal patch product, NEUPRO ® , a treatment for early stage Parkinson's disease. NEUPRO (rotigotine) is a dopamine agonist. In a double blind test, the product improved patients' ability to do routine daily tasks and their motor function scores compared to placebo. UCB expects to file for China approval this year; NEUPRO is already sold in the US, Europe and Japan. More details.... Stock Symbol: (EN: UVB) Share this with colleagues: // //